Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 296

Sort by

Sort Order Select

Journal Articles

Impact of Non- ABL1 Mutations on Outcomes in Patients with Chronic Myeloid Leukemia

Akriti G. Jain, Joy Nakitandwe, Krishna Desai, Genevieve M Crane, David S. Bosler, Jill O'Brien, Moaath K. Mustafa Ali, John C. Molina, Sophia Balderman, Anjali S. Advani, Hetty E. Carraway, Aaron T. Gerds, Abhay Singh, Matt Kalaycio, Sudipto Mukherjee

Blood (2024) 144 (Supplement 1): 3153.

https://doi.org/10.1182/blood-2024-209165

Published: 2024

Journal Articles

Cardiovascular Profile of Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia: A 16-Year Observational Study

Blood (2024) 144 (Supplement 1): 1777.

https://doi.org/10.1182/blood-2024-212146

Published: 2024

Journal Articles

Assessment of Secondary Malignancies after Allogeneic Hematopoietic Cell Transplant When Comparing Treatment with and without Post-Transplant Cyclophosphamide

Daniel P. Nurse, Wei Wei, Amanda Burns, Joseph Farinella, Deepa Jagadeesh, Robert M. Dean, Rabi Hanna, Seth J Rotz, Aaron T. Gerds, Claudio Brunstein, Matt Kalaycio, Craig S. Sauter, Betty K. Hamilton, Ronald Sobecks

Blood (2024) 144 (Supplement 1): 7383.

https://doi.org/10.1182/blood-2024-202626

Published: 2024

Journal Articles

Outcomes of Second-Line Tyrosine Kinase Inhibitors after First-Line Imatinib in Chronic Myelogenous Leukemia: A Retrospective Cohort Study

Muaz Alsabbagh Alchirazi, Hadil Zureigat, Ahmed N Mohamed, Aastha Dhakal, Ali Mushtaq, Naveen Rehman, Bryan Berube, Sneha Govande, Emily C. Zabor, Akriti G. Jain, John C. Molina, Sophia Balderman, Abhay Singh, Aaron T. Gerds, Anjali S. Advani, Hetty E. Carraway, Matt Kalaycio, Sudipto Mukherjee, Moaath K. Mustafa Ali

Blood (2024) 144 (Supplement 1): 6597.

https://doi.org/10.1182/blood-2024-206448

Published: 2024

Journal Articles

Prevalence and Outcomes of Opportunistic Infections in Steroid Refractory Graft Versus Host Disease Patients Treated with Ruxolitinib, Ibrutinib, and Belumosudil

Victoria Stepanyants, Hong Li, Danielle Cenin, Jessi Edwards, Claudio Brunstein, Matt Kalaycio, Ronald Sobecks, Craig S. Sauter, Betty K. Hamilton

Blood (2024) 144 (Supplement 1): 2145.

https://doi.org/10.1182/blood-2024-199329

Published: 2024

Journal Articles

Outcomes of Accelerated and Blast Phase Chronic Myeloid Leukemia at a Tertiary Center

Ahmed N Mohamed, Hadil Zureigat, Muaz Alsabbagh Alchirazi, Aastha Dhakal, Ali Mushtaq, Naveen Rehman, Bryan Berube, Sneha Govande, Emily C. Zabor, Akriti G. Jain, John C. Molina, Sophia Balderman, Abhay Singh, Aaron T. Gerds, Anjali S. Advani, Hetty E. Carraway, Matt Kalaycio, Sudipto Mukherjee, Moaath K. Mustafa Ali

Blood (2024) 144 (Supplement 1): 6610.

https://doi.org/10.1182/blood-2024-210152

Published: 2024

Journal Articles

Factors Associated with Platelet Engraftment Following Allogeneic Hematopoietic Cell Transplantation

Andrew D. Trunk, Hong Li, Matt Kalaycio, Ronald Sobecks, Claudio Brunstein, Craig S. Sauter, Betty K. Hamilton

Blood (2024) 144 (Supplement 1): 3488.

https://doi.org/10.1182/blood-2024-204051

Published: 2024

Journal Articles

Day 100 Risk Assessment Tool Predicts 1 Year Survival in Allogeneic Hematopoietic Cell Transplant Patients

Joseph Farinella, Lauren M Granat, Hong Li, Sharon M Caroniti, Pranay S. Hegde, Matt Kalaycio, Ronald Sobecks, Claudio Brunstein, Craig S Sauter, Betty K. Hamilton

Blood (2023) 142 (Supplement 1): 3725.

https://doi.org/10.1182/blood-2023-189629

Published: 2023

Journal Articles

Influence of Pre-Transplant Estimated Glomerular Filtration Rate (eGFR) on Outcomes after Allogeneic Hematopoietic Cell Transplantation

Ronald Sobecks, Hong Li, Danielle Cenin, Seema Patel, Jesse Edwards, Stephanie Farlow, Amelia Bragg, Rabi Hanna, Seth J Rotz, Deepa Jagadeesh, Aaron T. Gerds, Robert M. Dean, Brad Pohlman, Betty K. Hamilton, Claudio Brunstein, Matt Kalaycio, Craig S Sauter

Blood (2023) 142 (Supplement 1): 3621.

https://doi.org/10.1182/blood-2023-187071

Published: 2023

Journal Articles

Neighborhood Socioeconomic Disadvantage and Distance from Treatment Center Do Not Impact Survival Outcomes of Patients with Non-Hodgkin Lymphoma and Multiple Myeloma Treated with CAR T-Cell Therapies

Agrima Mian, Danai Dima, Betty K. Hamilton, Allison Winter, Jack Khouri, Louis S. Williams, Shahzad Raza, Deepa Jagadeesh, Aaron T. Gerds, Robert M. Dean, Matt Kalaycio, Claudio Brunstein, Craig S Sauter, Faiz Anwer, Brian T. Hill, Paolo Caimi

Blood (2023) 142 (Supplement 1): 7399.

https://doi.org/10.1182/blood-2023-188712

Published: 2023

Journal Articles

Risk of Venous Thromboembolism in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplant

Hussein Awada, Adel Hajj Ali, Beth M. Faiman, Allison Winter, Sandra Mazzoni, Christy J. Samaras, Craig S. Sauter, Willem J. van Heeckeren, Robert M. Dean, Brad Pohlman, Brian T. Hill, Jason Valent, Ronald M. Sobecks, Louis S. Williams, Deepa Jagadeesh, Betty K. Hamilton, Matt Kalaycio, Faiz Anwer, Jack Khouri

Blood (2022) 140 (Supplement 1): 10596–10597.

https://doi.org/10.1182/blood-2022-168810

Published: 2022

Journal Articles

Long-Term Outcomes of Delayed Neutrophil Engraftment Following Autologous Hematopoietic Cell Transplant in Multiple Myeloma

Blood (2022) 140 (Supplement 1): 12924–12925.

https://doi.org/10.1182/blood-2022-170385

Published: 2022

Journal Articles

Long-Term Outcomes of Autologous Hematopoietic Cell Transplant of Multiple Myeloma: A 10 Year Follow up Study

Blood (2022) 140 (Supplement 1): 12920–12921.

https://doi.org/10.1182/blood-2022-168262

Published: 2022

Journal Articles

Chip-Derived Vs De Novo Treatment-Related Myeloid Neoplasms after Autologous Stem Cell Transplant for Lymphoid Disorders

Hussein Awada, Carmelo Gurnari, Valeria Visconte, Teodora Kuzmanovic, Hassan Awada, James R. Cook, David S. Bosler, Brian J. Bolwell, Ronald M. Sobecks, Matt Kalaycio, Jaroslaw P. Maciejewski

Blood (2022) 140 (Supplement 1): 298–299.

https://doi.org/10.1182/blood-2022-167886

Published: 2022

Journal Articles

The Role of Corrected Dlco in Predicting Relapse and Mortality Post Autologous Hematopoietic Cell Transplantation in Multiple Myeloma

Blood (2022) 140 (Supplement 1): 10592–10593.

https://doi.org/10.1182/blood-2022-168433

Published: 2022

Journal Articles

Siltuximab for First-Line Treatment of Cytokine Release Syndrome: A Response to the National Shortage of Tocilizumab

Seema Patel, Danielle Cenin, Donna Corrigan, Betty K. Hamilton, Matt Kalaycio, Ronald M. Sobecks, Faiz Anwer, Jack Khouri, Robert M. Dean, Allison Winter, Deepa Jagadeesh, Brad Pohlman, Brian T. Hill, Craig S. Sauter, Paolo F. Caimi

Blood (2022) 140 (Supplement 1): 5073–5074.

https://doi.org/10.1182/blood-2022-169809

Published: 2022

Journal Articles

Venous Thromboembolism Is Associated with Inferior Survival after Allogeneic Hematopoietic Cell Transplant

Lauren M. Granat, Lisa A. Rybicki, Mailey L. Wilks, Christina Ferraro, Matt Kalaycio, Ronald M. Sobecks, Navneet S. Majhail, Dana E. Angelini, Betty K. Hamilton

Blood (2021) 138 (Supplement 1): 4866.

https://doi.org/10.1182/blood-2021-151230

Published: 2021

Journal Articles

Randomized Trial of Tacrolimus and Methotrexate Versus Tacrolimus, Reduced Dose Methotrexate, and Mycophenolate Mofetil for Prevention of Graft-Versus-Host Disease after Myeloablative Related and Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Betty K. Hamilton, Lisa A. Rybicki, Taylor Lucas, Donna Corrigan, Matt Kalaycio, Rabi Hanna, Seth J Rotz, Robert M. Dean, Aaron T. Gerds, Brian T. Hill, Deepa Jagadeesh, Brad Pohlman, Edward A. Copelan, Navneet S. Majhail

Blood (2021) 138 (Supplement 1): 99.

https://doi.org/10.1182/blood-2021-149686

Published: 2021

Journal Articles

Post-Transplant Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia

Leland Metheny, III, Ronald M. Sobecks, Christina Cho, Paolo F. Caimi, Navneet S. Majhail, Folashade Otegbeye, Kirsten M Boughan, Brenda W. Cooper, Erin Galloway, Molly Gallogly, Ehsan Malek, Benjamin Tomlinson, Aaron T. Gerds, Betty K. Hamilton, Matt Kalaycio, Sergio A Giralt, Marcos J.G. de Lima

Blood (2021) 138 (Supplement 1): 2899.

https://doi.org/10.1182/blood-2021-153041

Published: 2021

Journal Articles

Abnormal Metaphase Cytogenetics Adds to Currently Known Risk-Factors for Venous Thromboembolism in Multiple Myeloma: Derivation of the PRISM score

Rajshekhar Chakraborty, MD, Lisa Rybicki, MS, Jason Valent, MD, Alex V. Mejia Garcia, MD, Beth M. Faiman, PhDCNP, Jack Khouri, MD, Nathaniel Rosko, PharmD, Christy J. Samaras, DO, Matt Kalaycio, MD, Faiz Anwer, MD, Alok A Khorana, MD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-137525

Published: 2020

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Impact of Non- ABL1 Mutations on Outcomes in Patients with Chronic Myeloid Leukemia

Cardiovascular Profile of Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia: A 16-Year Observational Study

Assessment of Secondary Malignancies after Allogeneic Hematopoietic Cell Transplant When Comparing Treatment with and without Post-Transplant Cyclophosphamide

Outcomes of Second-Line Tyrosine Kinase Inhibitors after First-Line Imatinib in Chronic Myelogenous Leukemia: A Retrospective Cohort Study

Prevalence and Outcomes of Opportunistic Infections in Steroid Refractory Graft Versus Host Disease Patients Treated with Ruxolitinib, Ibrutinib, and Belumosudil

Outcomes of Accelerated and Blast Phase Chronic Myeloid Leukemia at a Tertiary Center

Factors Associated with Platelet Engraftment Following Allogeneic Hematopoietic Cell Transplantation

Day 100 Risk Assessment Tool Predicts 1 Year Survival in Allogeneic Hematopoietic Cell Transplant Patients

Influence of Pre-Transplant Estimated Glomerular Filtration Rate (eGFR) on Outcomes after Allogeneic Hematopoietic Cell Transplantation

Neighborhood Socioeconomic Disadvantage and Distance from Treatment Center Do Not Impact Survival Outcomes of Patients with Non-Hodgkin Lymphoma and Multiple Myeloma Treated with CAR T-Cell Therapies

Risk of Venous Thromboembolism in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplant

Long-Term Outcomes of Delayed Neutrophil Engraftment Following Autologous Hematopoietic Cell Transplant in Multiple Myeloma

Long-Term Outcomes of Autologous Hematopoietic Cell Transplant of Multiple Myeloma: A 10 Year Follow up Study

Chip-Derived Vs De Novo Treatment-Related Myeloid Neoplasms after Autologous Stem Cell Transplant for Lymphoid Disorders

The Role of Corrected Dlco in Predicting Relapse and Mortality Post Autologous Hematopoietic Cell Transplantation in Multiple Myeloma

Siltuximab for First-Line Treatment of Cytokine Release Syndrome: A Response to the National Shortage of Tocilizumab

Venous Thromboembolism Is Associated with Inferior Survival after Allogeneic Hematopoietic Cell Transplant

Randomized Trial of Tacrolimus and Methotrexate Versus Tacrolimus, Reduced Dose Methotrexate, and Mycophenolate Mofetil for Prevention of Graft-Versus-Host Disease after Myeloablative Related and Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Post-Transplant Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia

Abnormal Metaphase Cytogenetics Adds to Currently Known Risk-Factors for Venous Thromboembolism in Multiple Myeloma: Derivation of the PRISM score

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only